Engineering of NK activating receptor ligands enhances immune compatibility of MHC-I-/- iPSC-derived β cells for cell therapy of type 1 diabetes
Abstract
Publication Date:
2020
Short description:
Engineering of NK activating receptor ligands enhances immune compatibility of MHC-I-/- iPSC-derived β cells for cell therapy of type 1 diabetes / Chimienti, R., Baccega, T., Manenti, F., Torchio, S., Pellegrini, S., Cospito, A., Monti, P., Sordi, V., Lombardo, A., Malnati, M., Piemonti, L.. - In: CYTOTHERAPY. - ISSN 1465-3249. - 22:5(2020), pp. S15-S15.
Iris type:
1.5 Abstract in rivista
List of contributors:
Chimienti, R; Baccega, T; Manenti, F; Torchio, S; Pellegrini, S; Cospito, A; Monti, P; Sordi, V; Lombardo, A; Malnati, M; Piemonti, L
Published in: